GoAI
Get started
BillionToOne, Inc. logo

BillionToOne, Inc.

BLLN

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$95.03

−$0.24 · -0.25%

Aug 21, 4:00 PM ET

Pre-market

$94.99

−$0.04 · -0.04%

Aug 24, 8:46 AM ET

BLLN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

89

Deep Value

Momentum

75

Gaining

Sentiment

51

Mixed

Risk resilience

62

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Oguzhan Atay
Listed since
Nov 6, 2025
Employees
713

Market position

Day range

Current $95.03

52-week range

Current $95.03

Open
$95.64
Previous close
$95.27
Volume
588.73K
0.8× average
Average volume
732.28K
Average daily volume
Market cap
4.37B USD
Beta
0.34
Market reference 1
50-day average
$115.27
-17.56% below average
200-day average
$95.3429
-0.33% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
137.7×
P/B (TTM)
8.21×
P/S (TTM)
11×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
71.27%
Operating margin
10.90%
Net margin
8.43%

Financial health

Debt / equity
0.27×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends87%13%-60%-134%Gross margin, FY2023: 24.13%Gross margin, FY2024: 53.03%Gross margin, FY2025: 68.32%Operating margin, FY2023: -96.89%Operating margin, FY2024: -30.90%Operating margin, FY2025: 5.25%Net margin, FY2023: -115.27%Net margin, FY2024: -27.24%Net margin, FY2025: 2.44%FY2023FY2024FY2025
Gross margin FY2023 24.13%. Gross margin FY2024 53.03%. Gross margin FY2025 68.32%. Operating margin FY2023 -96.89%. Operating margin FY2024 -30.90%. Operating margin FY2025 5.25%. Net margin FY2023 -115.27%. Net margin FY2024 -27.24%. Net margin FY2025 2.44%.

Income trends

Revenue

305.11M USD+99.97%

Operating income

16.02M USD+63.17M USD

Net income

7.45M USD+49.02M USD
Income trends across reported periods343.89M USD188.77M USD33.66M USD−121.46M USDRevenue, FY2023: 71.73M USDRevenue, FY2024: 152.58M USDRevenue, FY2025: 305.11M USDOperating income, FY2023: −69.5M USDOperating income, FY2024: −47.15M USDOperating income, FY2025: 16.02M USDNet income, FY2023: −82.68M USDNet income, FY2024: −41.57M USDNet income, FY2025: 7.45M USDFY2023FY2024FY2025
Revenue FY2023 71.73M USD. Revenue FY2024 152.58M USD. Revenue FY2025 305.11M USD. Operating income FY2023 −69.5M USD. Operating income FY2024 −47.15M USD. Operating income FY2025 16.02M USD. Net income FY2023 −82.68M USD. Net income FY2024 −41.57M USD. Net income FY2025 7.45M USD.
Metric (USD)FY2025FY2024FY2023
Revenue305.11M USD152.58M USD71.73M USD
Cost of goods sold96.65M USD71.67M USD54.42M USD
Gross profit208.46M USD80.92M USD17.31M USD
Research and development49.38M USD36.6M USD22.41M USD
Selling, general, and administrative143.05M USD91.47M USD64.39M USD
Operating expenses192.44M USD128.06M USD86.8M USD
Interest income7.75M USD5.82M USD3.46M USD
Interest expense95K USD2.39M USD3.27M USD
Depreciation and amortization11.91M USD11.69M USD6.46M USD
Operating income16.02M USD−47.15M USD−69.5M USD
Net income7.45M USD−41.57M USD−82.68M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
40%
2 beats, 3 misses, 0 met estimates
Average EPS surprise
+639.26%
5 comparable reports
Latest EPS result
0.15
Estimate 0.18 · Miss by 18.17%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.380.230.09-0.06Q4 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q4 2025, reported Oct 7, 2025: actual -0.02, estimate 0.14, surprise -114.34%, Miss. Q4 2025, reported Dec 9, 2025: actual 0.1, estimate 0.14, surprise -28.32%, Miss. Q1 2026, reported Mar 4, 2026: actual 0.11, estimate 0.07, surprise +57.14%, Beat. Q2 2026, reported May 6, 2026: actual 0.34, estimate 0.01, surprise +3300.00%, Beat. Q3 2026, reported Aug 5, 2026: actual 0.15, estimate 0.183, surprise -18.17%, Miss. Q4 2026, reported Oct 6, 2026: actual —, estimate 0.154, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates120.95M101.29M81.62M61.95MQ4 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q4 2025, reported Oct 7, 2025: actual 66.6M USD, estimate 82.9M USD, surprise -19.66%, Miss. Q4 2025, reported Dec 9, 2025: actual 83.5M USD, estimate 82.9M USD, surprise +0.72%, Beat. Q1 2026, reported Mar 4, 2026: actual 96.05M USD, estimate 87.19M USD, surprise +10.17%, Beat. Q2 2026, reported May 6, 2026: actual 108.4M USD, estimate 97.14M USD, surprise +11.59%, Beat. Q3 2026, reported Aug 5, 2026: actual 109.4M USD, estimate 109.22M USD, surprise +0.17%, Beat. Q4 2026, reported Oct 6, 2026: actual —, estimate 116.3M USD, surprise —, Comparison unavailable.

BLLN news

gurufocus.com

/C O R R E C T I O N -- BillionToOne/

/C O R R E C T I O N -- BillionToOne/ PR Newswire MENLO PARK, Calif., Aug. 18, 2026 I

Read source
prnewswire.com

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results MENLO PARK, Calif.,…

Read source
defenseworld.net

Billiontoone, Inc. (NASDAQ:BLLN) Receives $126.71 Average PT from Brokerages

Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the…

Read source
seekingalpha.com

BillionToOne: A Softer Quarter After Heightened Expectations

BillionToOne experienced a sharp post-earnings sell-off despite maintaining full-year guidance and strong year-over-year revenue growth. Second quarter results showed slowing sequential growth, softer average selling…

Read source
zacks.com

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street…

Read source
marketbeat.com

Billiontoone Q2 Earnings Call Highlights

Billiontoone NASDAQ: BLLN reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular…

Read source

BLLN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BLLN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
100.73M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
72.64M
Weight
0.04%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
23.06M
Weight
0.03%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
20.98M
Weight
0.05%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
7.23M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
F/M Emerald Life Sciences Innovation ETF logoF/M Emerald Life Sciences Innovation ETFLFSC
Market value
5.19M
Weight
3.87%
AUM
74.65M USD
Expense ratio
0.54%
Price / 1D
$47.7953+0.83%
iShares U.S. Small-Cap Equity Factor ETF logoiShares U.S. Small-Cap Equity Factor ETFSMLF
Market value
2.86M
Weight
0.07%
AUM
4.3B USD
Expense ratio
0.15%
Price / 1D
$89.29+0.80%
T. Rowe Price Small-Mid Cap ETF logoT. Rowe Price Small-Mid Cap ETFTMSL
Market value
2.18M
Weight
0.07%
AUM
3B USD
Expense ratio
0.55%
Price / 1D
$43.59+0.60%

Continue in GoAI

Research BLLN

research.disclaimer